Partner
Matthew Luneack focuses on patent litigation before U.S. district courts as well as strategic client counseling. His practice covers a variety of technologies, including pharmaceuticals; biotechnology; chemical products and processes; and sports and fitness equipment.
Matthew is involved in all phases of district court litigation, from the initial pleadings through trial and post-trial. His experience includes developing claim construction, infringement, and validity positions; conducting fact and expert discovery; drafting briefs and motion materials; preparing witnesses; taking and defending depositions; arguing claim construction and evidentiary issues; and examining witnesses at trial. Matthew has particular experience representing pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act.
Matthew's counseling practice includes providing strategic advice through opinions of counsel, patent portfolio development and management, due diligence investigations, and freedom-to-operate analyses. He has been recognized by Best Lawyers as "One to Watch."
Prior to his legal career, Matthew gained experience as a research and development intern for Masco Corporation, studying innovative water-saving plumbing products.
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Represented Eli Lilly in patent litigations involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
Represented Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.
2:17-cv-10230, D.N.J., Judges Mannion, Salas
Duchesnay Inc. v. Actavis Laboratories FL, Inc. et al.
Represented Duchesnay in ANDA litigation in the District of Delaware against multiple generic drug manufacturers seeking to make a generic version of Bonjesta® (doxylaine succinate and phyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy.
1:18-cv-01895, D. Del., Judges Andrews, Fallon
Valeant Pharmaceuticals Int’l, Inc. v. Actavis Laboratories FL, Inc.
2:16-cv-09038, D.N.J., Judges Chesler, Waldor
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
1:15-cv-00687, D. Del., Judges Dyk, Sleet, Stark
Grünenthal GmbH v. Teva Pharmaceuticals
1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein
Articles
Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation
May 1, 2023
Bloomberg LawFederal Circuit IP Blog
Assignor Estoppel Has “No Place” in IPR Proceedings Assignor Estoppel Has “No Place” in IPR Proceedings
November 27, 2018
Federal Circuit IP Blog
Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting
November 16, 2018
Federal Circuit IP Blog
Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact
October 4, 2018
Award/Ranking
Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch
August 21, 2025
Best LawyersAward/Ranking
31 Finnegan Attorneys Recognized by Best Lawyers 31 Finnegan Attorneys Recognized by Best Lawyers
August 15, 2024
Best LawyersPress Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersAward/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
29 Finnegan Attorneys Ranked by Best Lawyers 29 Finnegan Attorneys Ranked by Best Lawyers
August 18, 2022
U.S. News—Best LawyersDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.